Study of a Novel Subcutaneous Depot Formulation of Buprenorphine
Status:
Completed
Trial end date:
2018-06-07
Target enrollment:
Participant gender:
Summary
INDV-6200 is being developed for the treatment of opioid dependency and is expected to
provide sustained buprenorphine plasma concentrations. The study will be done in healthy
volunteers and will administer a non-therapeutic dose of INDV-6200. Study Period 1 will
evaluate the oral tolerability of sublingual (SL) buprenorphine dosed over 3 days. Period 2
will administer the investigational medicinal product (IMP) or volume matched placebo.